


# Stabilis



## Ciprofloxacine lactate



Noms commerciaux

Aristin C	Grèce
Baycip	Chili, Espagne, Suède
Cepokab	Mexique
Ciflosin	Turquie
Ciflox	Arabie Saoudite, France
Cifloxin	Chili, Colombie, Malaisie
Cifoblas	Colombie
Cifran	Inde
Ciprine	Inde, Suisse
Ciprinol	Croatie, Pologne, Roumanie
Ciprivax	Vénézuela
Cipro	Canada, Etats Unis d'Amérique, Turquie
Ciprobay	Allemagne, Arabie Saoudite, Croatie, Emirats Arabes Unis, Hongrie, Slovénie
Ciprobid	Inde
Ciproflox	Mexique
Ciprofloxacine	Allemagne, Autriche, Canada, Danemark, Finlande, Grande Bretagne, Grèce, Hongrie, Italie, Norvège, Pays bas, Pologne, Suède
Ciprofloxacina	Argentine, Colombie, Portugal, Roumanie, Vénézuela
Ciprofloxacine	Belgique, Maroc, Suisse
Ciprofloxacino	Chili, Colombie, Espagne
Ciprohexal	Allemagne
Ciproktan	Turquie
Cipromed	Croatie
Ciproxan	Japon
Ciproxin	Australie, Autriche, Grande Bretagne, Grèce, Italie, Suède, Suisse, Turquie
Ciproxina	Equateur, Mexique, Portugal, Vénézuela
Ciproxine	Belgique, Luxembourg, Maroc, Suisse
Ciproxino	Chili
Cisplatine	
Citeral	Croatie
Estecina	Espagne
Ladinin	Malaisie
Nafloxin	Grèce
Proxacin	Pologne

Topistin	Grèce
Truoxin	Irlande



## Stabilité des solutions

PVC		? mg/ml	25°C		90			666
PVC		? mg/ml	5°C		90			666
PVC		1 mg/ml	2-8°C		30			3231
PVC		1 mg/ml	21-24°C		30			3231
PVC		1 mg/ml	29-31°C		30			3231
PVC		1,5 mg/ml	25°C		48			434
PVC		2 mg/ml	2-8°C		30			3231
PVC		2 mg/ml	21-24°C		30			3231
PVC		2 mg/ml	29-31°C		30			3231
PVC		0,025 mg/ml	25°C		7			4263
PVC		0,025 mg/ml	37°C		48			4263
PVC		0,025 mg/ml	25°C		7			4263
PVC		0,025 mg/ml	37°C		48			4263
PVC		0,025 mg/ml	20°C		42			2368
PVC		0,025 mg/ml	37°C		42			2368
PVC		0,025 mg/ml	4°C		42			2368

PVC		47,6 mg/ml	25°C		7			4460
PVC		47,6 mg/ml	37°C		24			4460
PVC		47,6 mg/ml	6°C		14			4460
PVC		47,6 mg/ml	25°C		7			4460
PVC		47,6 mg/ml	37°C		24			4460
PVC		47,6 mg/ml	6°C		14			4460
PVC		47,6 mg/ml	37°C		24			4460
PVC		47,6 mg/ml	6°C		14			4460
PVC		47,6 mg/ml	25°C		48			4460
PVC		47,6 mg/ml	37°C		24			4460
PVC		47,6 mg/ml	6°C		14			4460
PVC		47,6 mg/ml	25°C		48			4460
PVC		47,6 mg/ml	37°C		24			4460
PVC		47,6 mg/ml	6°C		14			4460
EVA		4 mg/ml	23°C		7			1614
EVA		4 mg/ml	4°C		30			1614
PI		5 & 20 mg/ml	25°C		30			604
PI		5 & 20 mg/ml	4°C		90			604



## Stabilité en mélange

PVC		1,5 mg/ml	25°C		Gentamicin sulfate : 1 mg/ml	48		434
PVC		1,5 mg/ml	25°C		Tobramycin sulfate : 1 mg/ml	48		434
PVC		1,5 mg/ml	25°C		Amikacin sulfate : 1,5 mg/ml	48		434
PVC		1,5 mg/ml	25°C		Metronidazole : 4 mg/ml	48		434
PVC		1,5 mg/ml	4°C		Gentamicin sulfate : 1 mg/ml	48		434
PVC		1,5 mg/ml	4°C		Tobramycin sulfate : 1 mg/ml	48		434
PVC		1,5 mg/ml	4°C		Metronidazole : 4 mg/ml	48		434
PVC		1,5 mg/ml	4°C		Amikacin sulfate : 1,5 mg/ml	48		434
POF		4 mg/ml	23°C		Linezolid : 2 mg/ml	7		1668
POF		4 mg/ml	4°C		Linezolid : 2 mg/ml	24		1668



## Facteur influençant la stabilité

				948
				3475
				301
				14 285 288
				500



## Compatibilités

	Ciprofloxacin lactate : 1 mg/ml Amifostine : 10 mg/ml		3	
				434
	Ciprofloxacin lactate : 1.5 mg/ml Amikacin sulfate : 4 mg/ml		285	
	Ciprofloxacin lactate : 2 mg/ml Amikacin sulfate : 5 mg/ml			288
				434
	Ciprofloxacin lactate : 2 mg/ml Aminophylline : 2 mg/ml			434
	Ciprofloxacin lactate : 1.5 mg/ml Aminophylline : 1.2 mg/ml			434
	Ciprofloxacin lactate : 2 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611	
	Ciprofloxacin lactate Amoxicillin sodium		3529	
	Ciprofloxacin lactate : 2 mg/ml Amoxicillin sodium : 10 mg/ml		1357	
	Ciprofloxacin lactate : 2 mg/ml Amoxicillin sodium / clavulanic acid : 12 mg/ml		1357	
	Ciprofloxacin lactate Amoxicillin sodium / clavulanic acid		3529	
	Ciprofloxacin lactate : 2 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824	
	Ciprofloxacin lactate : 2 mg/ml Amphotericin B : 0.1 mg/ml		285	
	Ciprofloxacin lactate : 1 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921	
	Ciprofloxacin lactate : 2.6 mg/ml Ampicillin sodium : 20 mg/ml		1392	
	Ciprofloxacin lactate : 2,6 mg/ml Ampicillin sodium : 20 mg/ml		1758	
	Ciprofloxacin lactate Ampicillin sodium		3529	
	Ciprofloxacin lactate : 2 mg/ml Ampicillin sodium - sulbactam sodium : 30 mg/ml		285	

		Ciprofloxacin lactate Ampicillin sodium - sulbactam sodium		3529
		Ciprofloxacin lactate Ampicillin sodium - sulbactam sodium		1500
		Ciprofloxacin lactate : 2 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Ciprofloxacin lactate : 2 mg/ml Atracurium besylate : 2 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml Azithromycine : 2 mg/ml		1800
		Ciprofloxacin lactate : 1 mg/ml Aztreonam : 20 mg/ml		500
		Ciprofloxacin lactate : 1 mg/ml Aztreonam : 40 mg/ml		99
		Ciprofloxacin lactate : 2 mg/ml Aztreonam : 40 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml Bivalirudin : 5 mg/ml		1713
		Ciprofloxacin lactate : 2 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Ciprofloxacin lactate : 2 mg/ml Caffeine : 10 mg/ml		3964
		Ciprofloxacin lactate : 2 mg/ml Calcium gluconate : 100 mg/ml		261
		Ciprofloxacin lactate : 2 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Ciprofloxacin lactate : 2 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Ciprofloxacin lactate : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Ciprofloxacin lactate : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Ciprofloxacin lactate : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Ciprofloxacin lactate : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	<b>RL</b>	3249
		Ciprofloxacin lactate Ceftazidime		3883
		Ciprofloxacin lactate : 1 mg/ml Ceftazidime : 20 mg/ml		500
		Ciprofloxacin lactate : 2 mg/ml Ceftazidime : 20 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	<b>RL</b>	2269
		Ciprofloxacin lactate Ceftobiprole medocaril sodium		4650
		Ciprofloxacin lactate : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Ciprofloxacin lactate : 2 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Ciprofloxacin lactate : 2 mg/ml Cefuroxime sodium : 30 mg/ml		285

	Ciprofloxacin lactate : 2 mg/ml Ciclosporin : 0,5 mg/ml		289
	Ciprofloxacin lactate : 2 mg/ml Cimetidine hydrochloride : 1.2 mg/ml		285
	Ciprofloxacin lactate : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
			3526
			434
			3529
			3012
	Ciprofloxacin lactate Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
	Ciprofloxacin lactate : 2 mg/ml Defibrotide : 8 mg/ml		3728
			288
	Ciprofloxacin lactate : 2 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		1712
	Ciprofloxacin lactate : 2 mg/ml Digoxin : 250 µg/ml		289
	Ciprofloxacin lactate : 2 mg/ml Digoxin : 250 µg/ml		288
	Ciprofloxacin lactate : 2 & 10 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
	Ciprofloxacin lactate Dimenhydrinate		2087
	Ciprofloxacin lactate : 2 mg/ml Diphenhydramine hydrochloride : 50 mg/ml		288
	Ciprofloxacin lactate : 2 mg/ml Dobutamine hydrochloride : 2 mg/ml		285
	Ciprofloxacin lactate : 2 mg/ml Dobutamine hydrochloride : 0.25 mg/ml		288
	Ciprofloxacin lactate : 1 mg/ml Docetaxel : 0.9 mg/ml		1754
	Ciprofloxacin lactate : 2 mg/ml Dopamine hydrochloride : 1.6 mg/ml		288
	Ciprofloxacin lactate : 2 mg/ml Doripenem : 5 mg/ml		2262
	Ciprofloxacin lactate : 1 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
	Ciprofloxacin lactate : 2 mg/ml Eravacycline : 0,6 mg/ml		4434
	Ciprofloxacin lactate : 2 mg/ml Esmolol hydrochloride : 10 mg/ml		3879
	Ciprofloxacin lactate : 1 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Ciprofloxacin lactate : 2 mg/ml Fenoldopam mesylate : 80 µg/ml		1803



		Ciprofloxacin lactate : 2 mg/ml Flucloxacillin sodium : 10 mg/ml	∅	1357
		Ciprofloxacin lactate Flucloxacillin sodium		3529
		Ciprofloxacin lactate : 2 mg/ml Fluconazole : 1 mg/ml	◆	285
		Ciprofloxacin lactate : 2 mg/ml Fosfomycin : 30 mg/ml	▲	4055
		Ciprofloxacin lactate : 2 mg/ml Fosfomycin : 30 mg/ml	◆	4055
		Ciprofloxacin lactate : 2 mg/ml Furosemide : 10 mg/ml	▲◆	288
		Ciprofloxacin lactate : 2 mg/ml Furosemide : 5 mg/ml	▲	289
		Ciprofloxacin lactate : 2 mg/ml Gallium nitrate : 1 mg/ml	▲	91
		Ciprofloxacin lactate : 1 mg/ml Gemcitabine hydrochloride : 10 mg/ml	▲	1423
		Ciprofloxacin lactate : 2 mg/ml Gentamicin sulfate : 10 mg/ml	▲	289
		Ciprofloxacin lactate : 1.5 mg/ml Gentamicin sulfate : 1 mg/ml	▲◆	434
		Ciprofloxacin lactate : 2 mg/ml Gentamicin sulfate : 1.6 mg/ml	▲◆	288
		Ciprofloxacin lactate : 2 mg/ml Gentamicin sulfate : 1.6 mg/ml	◆	285
		Ciprofloxacin lactate : 1 mg/ml Granisetron hydrochloride : 0.05 mg/ml	◆	182
		Ciprofloxacin lactate : 0.2 mg/ml Heparin sodium : 10 & 100 UI/ml	▲	2057
		Ciprofloxacin lactate : 0.4 & 0.6 mg/ml Heparin sodium : 10 >> 1000 UI/ml	▲	2057
		Ciprofloxacin lactate : 0.8 mg/ml Heparin sodium : 10 >> 5000 UI/ml	▲	2057
		Ciprofloxacin lactate : 1 mg/ml Heparin sodium : 10 >> 10000 UI/ml	▲	2057
		Ciprofloxacin lactate : 0.1 mg/ml Heparin sodium : 10 >> 10000 UI/ml	▲	2057
		Ciprofloxacin lactate : 0.2 mg/ml Heparin sodium : 1000 >> 10000 UI/ml	▲	2057
		Ciprofloxacin lactate : 2 mg/ml Heparin sodium : 10 >> 1000 UI/ml	▲	289
		Ciprofloxacin lactate : 0.8 mg/ml Heparin sodium : 10000 UI/ml	▲	2057
		Ciprofloxacin lactate : 2 mg/ml Heparin sodium : 100 UI/ml	▲◆	288
		Ciprofloxacin lactate : 2 mg/ml	RL	4603
		Ciprofloxacin lactate : 2 mg/ml		4441
		Ciprofloxacin lactate : 2 mg/ml		4440
		Ciprofloxacin lactate : 1 mg/ml		1415












		Ciprofloxacin lactate : 2 mg/ml Heparin sodium : 10 UI/ml		1393
		Ciprofloxacin lactate : 1 mg/ml		301
		Ciprofloxacin lactate		3985
		Ciprofloxacin lactate : 2 mg/ml		261
		Ciprofloxacin lactate		285
		Ciprofloxacin lactate : 2 mg/ml		288
		Ciprofloxacin lactate Heparin sodium		3529
		Ciprofloxacin lactate Heparin sodium		3540
		Ciprofloxacin lactate : 0.4 & 0.6 mg/ml Heparin sodium : 5000 & 10000 UI/ml		2057
		Ciprofloxacin lactate : 2 mg/ml Hetastarch : 60 mg/ml		1721
		Ciprofloxacin lactate : 2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4550
		Ciprofloxacin lactate : 2 mg/ml Hydrocortisone sodium succinate : 50 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4465
		Ciprofloxacin lactate : 2 mg/ml Hydroxyzine dihydrochloride : 50 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Ciprofloxacin lactate : 2 mg/ml Labetalol hydrochloride : 5 mg/ml		3879
		Ciprofloxacin lactate : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Ciprofloxacin lactate : 2 mg/ml Lidocaine hydrochloride : 40 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Lidocaine hydrochloride : 20 mg/ml		288
		Ciprofloxacin lactate : 1 mg/ml Linezolid : 2 mg/ml		1925
		Ciprofloxacin lactate : 4 mg/ml Linezolid : 2 mg/ml		1668
		Ciprofloxacin lactate : 2 mg/ml Lorazepam : 0.33 mg/ml		186
		Ciprofloxacin lactate : 2 mg/ml Magnesium sulfate : 240 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Magnesium sulfate : 500 mg/ml		261
		Ciprofloxacin lactate : 2 mg/ml Magnesium sulfate : 240 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Meropenem : 20 mg/ml		3475
		Ciprofloxacin lactate : 2 mg/ml Meropenem : 50 mg/ml		4319



		Ciprofloxacin lactate : 2 mg/ml Methylprednisolone sodium succinate : 62.5 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Metoclopramide hydrochloride : 5 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Metoclopramide hydrochloride : 5 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Metoprolol tartrate : 0.4 mg/ml		3879
		Ciprofloxacin lactate : 2 mg/ml Metronidazole : 2.5 mg/ml		285
		Ciprofloxacin lactate : 1.5 mg/ml Metronidazole : 4 mg/ml		434
		Ciprofloxacin lactate : 2 mg/ml Metronidazole : 5 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Midazolam hydrochloride : 5 mg/ml		186
		Ciprofloxacin lactate : 2 mg/ml Midazolam hydrochloride : 0.2 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml N-acetylcysteine : 200 mg/ml		3766
		Ciprofloxacin lactate Nafcillin sodium		3529
		Ciprofloxacin lactate : 2 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Ciprofloxacin lactate : 2 mg/ml Netilmicin sulfate : 2,5 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Ciprofloxacin lactate Oxacillin sodium		3529
		Ciprofloxacin lactate : 2 mg/ml Pancuronium bromide : 0.2 mg/ml		285
		Ciprofloxacin lactate Pantoprazole sodium		2090
		Ciprofloxacin lactate : 2 mg/ml Paracetamol : 10 mg/ml		4742
		Ciprofloxacin lactate : 2 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Ciprofloxacin lactate Penicillin G potassium		3529
		Ciprofloxacin lactate Penicillin G sodium		3529
		Ciprofloxacin lactate : 2 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Ciprofloxacin lactate : 0,5 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Ciprofloxacin lactate : 2 mg/ml Phenytoin sodium : 50 mg/ml		288
		Ciprofloxacin lactate : 1 mg/ml Phloroglucinol : 2,5 mg/ml		3791

		Ciprofloxacin lactate Piperacillin sodium		3529
		Ciprofloxacin lactate : 2 mg/ml Piperacillin sodium : 40 mg/ml		285
		Ciprofloxacin lactate : 1 mg/ml Piperacillin sodium : 40 mg/ml		500
		Ciprofloxacin lactate Piperacillin sodium / tazobactam		3529
		Ciprofloxacin lactate : 2 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Ciprofloxacin lactate Posaconazole		4380
		Ciprofloxacin lactate : 2 mg/ml Potassium chloride : 40 mEq/l		289
		Ciprofloxacin lactate : 2 mg/ml Potassium chloride : 40 mEq/l		285
		Ciprofloxacin lactate : 2 mg/ml Potassium chloride : 2000 mEq/l		261
		Ciprofloxacin lactate : 2 mg/ml Potassium chloride : 40 mEq/l		288
		Ciprofloxacin lactate : 2 mg/ml Potassium phosphate : 3 mmol/ml		261
		Ciprofloxacin lactate : 2 mg/ml Promethazine hydrochloride : 25 mg/ml		288
		Ciprofloxacin lactate : 1 mg/ml Propofol : 10 mg/ml		300
		Ciprofloxacin lactate : 1 mg/ml Quinupristine/dalfopristine : 2 mg/ml		1513
		Ciprofloxacin lactate : 2 mg/ml Ranitidine hydrochloride : 2 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Ranitidine hydrochloride : 0,5 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		288
		Ciprofloxacin lactate : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
		Ciprofloxacin lactate : 2 mg/ml Salbutamol sulfate : 1 mg/ml		3216
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 8,4 >> 84 mg/ml		14
		Ciprofloxacin lactate : 1 mg/ml Sodium bicarbonate : 8,4 >> 42 mg/ml		14
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 63 & 84 mg/ml		14
		Ciprofloxacin lactate : 1 mg/ml Sodium bicarbonate : 63 & 84 mg/ml		14
		Ciprofloxacin lactate : 10 mg/ml Sodium bicarbonate : 8.4 mg/ml		269
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 0,84 mg/ml		289
		Ciprofloxacin lactate : 1 mg/ml Sodium bicarbonate : 8,4 >> 42 mg/ml		14

		Ciprofloxacin lactate : 10 mg/ml Sodium bicarbonate : 84 mg/ml		269
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 4 mg/ml		285
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 8,4 >> 42 mg/ml		14
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 84 mg/ml		288
		Ciprofloxacin lactate : 2 mg/ml Sodium bicarbonate : 84 mg/ml		288
		Ciprofloxacin lactate : 1 mg/ml Sodium bicarbonate : 63 & 84 mg/ml		14
		Ciprofloxacin lactate : 2 mg/ml Sodium Phosphate : 3 mmol/ml		261
		Ciprofloxacin lactate		3475
		Ciprofloxacin lactate : 2 mg/ml Sodium Phosphate : 0,3 mmol/ml		268
		Ciprofloxacin lactate : 2 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Ciprofloxacin lactate : 1 mg/ml Tacrolimus : 1000 µg/ml		479
		Ciprofloxacin lactate : 2 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Ciprofloxacin lactate : 2 mg/ml Teicoplanine : 60 mg/ml		289
		Ciprofloxacin lactate : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml		3254
		Ciprofloxacin lactate : 2 mg/ml Telavancin hydrochloride : 7.5 mg/ml	RL	3254
		Ciprofloxacin lactate Temocilline		4470
		Ciprofloxacin lactate Temocilline		3529
		Ciprofloxacin lactate : 2 mg/ml Temocilline : 83.33 mg/ml		2231
		Ciprofloxacin lactate : 2 mg/ml Teniposide : 0.1 mg/ml		905
		Ciprofloxacin lactate : 2 mg/ml Thiopental sodium : 25 mg/ml		3767
		Ciprofloxacin lactate : 1 mg/ml Thiotepa : 1 mg/ml		249
		Ciprofloxacin lactate : 2 mg/ml Ticarcillin / clavulanic acid : 30 mg/ml		285
		Ciprofloxacin lactate Ticarcillin / clavulanic acid		3529
		Ciprofloxacin lactate : 1.5 mg/ml Tobramycin sulfate : 1 mg/ml		434
		Ciprofloxacin lactate : 2 mg/ml Tobramycin sulfate : 1.6 mg/ml		285
		Ciprofloxacin lactate : 1 mg/ml Tobramycin sulfate : 1,6 mg/ml		500

	Ciprofloxacin lactate : 2 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Ciprofloxacin lactate : 2 mg/ml Vasopressin : 0.2 UI/ml		2017
	Ciprofloxacin lactate : 2 mg/ml Vecuronium bromide : 0.2 mg/ml		285
	Ciprofloxacin lactate : 2 mg/ml Verapamil hydrochloride : 2.5 mg/ml		288
 	Ciprofloxacin lactate : 2 mg/ml Warfarin sodium : 2 mg/ml		315



## Voie d'administration



## Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
14	Revue	Gilbert DL, Trissel LA, Martinez JF. Compatibility of ciprofloxacin lactate with sodium bicarbonate during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1193-1195.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
91	Revue	Lober CA, Dollard PA. Visual compatibility of gallium nitrate with selected drugs during Y-site injection. Am J Hosp Pharm 1993 ; 50: 1208-1210.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
186	Revue	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198	Revue	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.

251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
261	Revue	Percy LA, Rho JP. Visual compatibility of ciprofloxacin with selected components of total parenteral nutrient solutions during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 715-716.
268	Revue	Benjamin BE. Ciprofloxacin and sodium phosphate not compatible during actual Y-site injection. Am J Health-Syst Pharm 1996 ; 53: 1850-1851.
269	Revue	Trissel LA. Concentration-dependent precipitation of sodium bicarbonate with ciprofloxacin lactate. Am J Health-Syst Pharm 1996 ; 53: 84-85.
285	Revue	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
288	Revue	Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962.
289	Revue	Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707.
299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
315	Revue	Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600.
434	Revue	Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171.
479	Revue	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
500	Revue	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
604	Laboratoire	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
666	Revue	Mathew M, Das Gupta V, Zerai T. Stability of ciprofloxacin in 5% dextrose and normal saline injections. J Clin Pharm Ther 1994 ; 19: 261-262.

905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
948	Revue	Tiefenbacher EM, Haen E, Przybilla B, Kurz H. Photodegradation of some quinolones used as antimicrobial therapeutics. J Pharm Sci 1994 ; 83: 463-467.
1357	Revue	Janknegt R, Schrouff GGM, Hooymans PM, Hermens WJHH, Lohman JJHM. Quinolones and penicillins incompatibility. Ann Pharmacotherapy 1989 ; 23: 91-92.
1392	Revue	Lewis GM, Donnelly RF. Ampicillin and ciprofloxacin incompatibility. Can J Hosp Pharm 1999 ; 52: 90.
1393	Revue	Lyall D, Blythe J. Ciprofloxacin lactate infusion. Pharm J 1987 ; 238: 290.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1500	Revue	Melonakos TK. Ciprofloxacin-ampicillin sulbactam incompatibility. Ann Pharmacotherapy 1996 ; 30: 87.
1513	Laboratoire	Quinupristine / dalfopristine (Synercid®) - Résumé des caractéristiques du produit Monarch Pharmaceuticals Ireland 2006
1611	Revue	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1614	Revue	Trissel LA, Xu QA, Zhang Y, Saenz CA, Ingram DS. Stability of ciprofloxacin and vancomycin hydrochloride in autodose infusion system bags. Hosp Pharm 2001 ; 36: 1170-1173.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1668	Revue	Zhang Y, Xu QA, Trissel LA, Williams KY. Compatibility and stability of linezolid injection admixed with three quinolone antibiotics. Ann Pharmacotherapy 2000 ; 34: 996-1001.
1712	Revue	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Revue	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.



1721	Revue	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1758	Revue	Lewis GM, Donnelly RF. Ampicillin and ciprofloxacin incompatibility. Can J Hosp Pharm 1999 ; 52: 90.
1800	Revue	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Revue	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017	Revue	Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
2057	Revue	Droste JC, Jeraj HA, MacDonald A, Farrington K. Stability and in vitro efficacy of antibiotic-heparin lock solutions potentially useful for treatment of central venous catheter-related sepsis. J Antimicrob Chemother 2003 ; 51: 849-855.
2087	Revue	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2231	Revue	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.
2233	Revue	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	Revue	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.

2269	Revue	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2368	Revue	Mawhinney WM, Adair CG, Gorman SP, McClurg B. Stability of ciprofloxacin in peritoneal dialysis solution Am J Hosp Pharm 1992 ; 49: 2956 - 2959.
3012	Revue	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3152	Revue	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3216	Revue	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3231	Revue	Donnelly RF. Stability of Ciprofloxacin in Polyvinylchloride Minibags. Can J Hosp Pharm 2011 ; 64, 4 : 252-256.
3249	Revue	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3385	Revue	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Revue	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3475	Revue	Chen L.Y, Chen J, Waters V, Boodhan S. Incompatibility of ciprofloxacin and meropenem injections. Am J Health-Syst Pharm 2013 ;70:1966-1970.
3526	Laboratoire	Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010
3529	Laboratoire	Ciprofloxacin – Summary of Product Characteristics Hospira 2013
3540	Laboratoire	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3728	Revue	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Revue	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Revue	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.











3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	Revue	Foushee Jaime A, Meredith Pmichalee, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
3883	Laboratoire	Ceftazidime - Résumé des caractéristiques du produit Arrow 2016
3964	Revue	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Revue	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3985	Poster	Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M. Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro. Hopipharm Congress 2017 - Nancy 2017
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempta T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4263	Revue	Kane MP, Bailie GR, Moon DG, Siu I. Stability of ciprofloxacin injection in peritoneal dialysis solutions. Am J Hosp Pharm 1994 ;51:373-377
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4380	Laboratoire	Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4440	Revue	Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233.

4441	Revue	Gostynska, A, Stawny M, Dettlaff K, Jelinska A. The Interactions between Ciprofloxacin and Parenteral Nutrition Admixtures. Pharmaceutics 2020 ; 12, 27
4460	Revue	Kussmann M, Ferth A, Obermüller M, Pichler P, Zeitlinger M, Wiesholzer , Burgmann H, Poepl W, Reznicek G. Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Scientific reports 2019 9:6512
4465	Revue	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4470	Revue	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Revue	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4550	Revue	Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. Crit Care Resusc 2013 ;15, 1: 63–66.
4603	Revue	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4650	Laboratoire	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d’administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:



# Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Non précisée
 Jour	 A l'abri de la lumière
 Lumière	 Heure
 Dianéal® PD1 1.5% glucose (Baxter)	 Dianéal® PD1 4.25% glucose (Baxter)
 Dianéal® PD1 1.36% glucose (Baxter)	 Extraneal® (Baxter)
 Nutri neal®	 Physionéal® 1.36 (Baxter)
 Physionéal® 2.27 (Baxter)	 Physionéal® 3.86 (Baxter)
 Ethylène vinyl acétate	 Chlorure de sodium 0,9%
 Elastomère en polyisoprène	 Stabilité en mélange
 Solvant	 Molécule
 Polyolefine	 Aucun
 Facteur influençant la stabilité	 Provoque
 Dégradation	 Nutrition parentérale (mélange binaire)
 NaHCO <sub>3</sub>	 Précipitation
 Compatibilités	 Compatible
 Glucose 5%	 Instabilité chimique
 Incompatible	 Précipitation en 15 minutes
 Précipitation en 4 heures	 Incompatibilité non précisée
 Précipitation immédiate	 Turbidité en 4 heures
<b>RL</b> Ringer lactate	 Modification du pH > 1 unité pH
 Précipitation en 24 heures	 Incompatibilité subvisuelle
 Eau pour préparation injectable	 Précipitation en 1 heure
 Turbidité immédiate	 Turbidité en 15 minutes

	Nutrition parentérale (mélange ternaire)		Instabilité de l'émulsion en 1 heure
	Changement de couleur après 1 heure		Solvant spécifique
	Changement de couleur à 4 heures		Chlorure de sodium 0,45%
	Voie d'administration		Perfusion intraveineuse
	Bibliographie		Dictionnaire